ME
23andMe Holding Co.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.61
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 174.9M | 189.9M | 219.6M | 299.5M | 271.9M |
| Cost of Revenue | 81.6M | 89.9M | 120.3M | 165.0M | 138.9M |
| Gross Profit | 93.3M | 100.0M | 99.4M | 134.5M | 132.9M |
| Operating Expenses | |||||
| R&D Expense | 97.2M | 101.6M | 205.4M | 222.6M | 189.4M |
| SG&A Expense | 156.2M | 172.3M | 208.6M | 235.9M | 197.7M |
| General & Admin Expense | 111.9M | 132.3M | 150.0M | 116.0M | 97.4M |
| Selling & Marketing Expense | 44.3M | 40.0M | 58.6M | 119.9M | 100.3M |
| Other Expenses | 55.5M | 66.7M | 6.8M | — | — |
| Total Operating Expenses | 309.0M | 340.6M | 420.7M | 458.5M | 387.1M |
| Cost and Expenses | 374.3M | 430.5M | 541.0M | 623.5M | 526.0M |
| Operating Income (EBIT) | (199.4M) | (240.6M) | (321.4M) | (324.0M) | (254.2M) |
| Non-Operating | |||||
| Interest Income | 4.1M | 6.6M | 14.3M | 9.7M | 277.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.1M | 6.6M | 14.3M | 9.7M | 277.0K |
| Other Non-Op Income/Expense | 2.9M | 5.4M | (345.3M) | 9.6M | 33.2M |
| Non-Operating Income (excl Interest) | (58.9M) | (61.4M) | — | (9.6M) | — |
| EBT (Pre-Tax Income) | (196.5M) | (235.2M) | (666.6M) | (314.4M) | (221.0M) |
| Income Tax Expense | (6.8M) | (41.0K) | 73.0K | (2.8M) | (3.5M) |
| Bottom Line | |||||
| Net Income | (235.3M) | (280.9M) | (666.7M) | (311.7M) | (217.5M) |
| Earnings from Cont. Ops | (216.6M) | (235.2M) | (666.7M) | (311.7M) | (217.5M) |
| Earnings from Discont. Ops | (18.8M) | (45.7M) | — | — | — |
| Bottom Line Net Income | (235.3M) | (280.9M) | (666.7M) | (311.7M) | (217.5M) |
| Per Share | |||||
| Basic EPS | ($9.05) | ($10.88) | ($27.59) | ($13.81) | ($9.96) |
| Diluted EPS | ($9.05) | ($10.88) | ($28.01) | ($13.80) | ($9.96) |
| Revenue Per Share | $6.36 | $7.36 | $9.09 | $13.27 | $12.46 |
| Shares | |||||
| Basic Shares Outstanding | 27.5M | 25.8M | 24.2M | 22.6M | 21.8M |
| Diluted Shares Outstanding | 27.5M | 25.8M | 23.8M | 22.6M | 21.8M |
| Profitability Metrics | |||||
| EBITDA | (141.2M) | (155.9M) | (291.9M) | (277.9M) | (228.0M) |
| D&A | 21.6M | 23.4M | 29.5M | 36.5M | 26.1M |
| EBIT | (162.9M) | (179.2M) | (321.4M) | (314.4M) | (254.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2025